I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.

Related Articles

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.

Semin Nucl Med. 2016 May;46(3):203-14

Authors: Carrasquillo JA, Pandit-Taskar N, Chen CC

Abstract
Pheochromocytomas and paragangliomas are rare tumors arising from chromaffin cells. Available therapeutic modalities consist of chemotherapy, tyrosine kinase inhibitors, and I-131 metaiodobenzylguanidine (MIBG). I-131 MIBG is taken up via specific receptors and localizes into many but not all pheochromocytomas and paragangliomas. Because these tumors are rare, most therapy studies are retrospective presentations of clinical experience. Numerous retrospective studies and a few prospective studies have shown favorable responses in this disease, including symptomatic, biochemical, and objective responses. In this report, we review the experience of using I-131 MIBG therapy for targeting pheochromocytoma and paragangliomas.

PMID: 27067501 [PubMed - indexed for MEDLINE]

http://ift.tt/2iaHRgu